Galera Therapeutics (GRTX) Investor Presentation - Slideshow

Top centers where >80% HNC patients are treated Most Centers Have Ability to Infuse Avasopasem Today Galera 36% 31% Proctitis Dermatitis Esophagitis Patients at risk of experiencing 20% Esophagitis in Lung Cancer Initial Target Population ©2023 Galera Therapeutics, Inc. 28 | --- | --- | --- | --- | |-------|----------------------------------------|------------------------------------|-----------------------------------------------| | | | | | | | 50-60% Get Grade 2+1 | Current Approaches | AESOP Trial Design ...